ライフサイエンスコーパス: dexfenfluramine

1 the voluntary withdrawal of fenfluramine and dexfenfluramine.

2 as pulmonary vascular effects reminiscent of dexfenfluramine.

3 rexic agents: fenfluramine and its d-isomer, dexfenfluramine.

4 ollowing anorexigen treatment were uncommon (dexfenfluramine, 2.3%; phentermine/fenfluramine, 2.4%, a

5 ntrol analysis of 6532 subjects who received dexfenfluramine, 2371 who received fenfluramine, and 862

6 patients), investigational sustained-release dexfenfluramine (352 patients), or placebo (354 patients

7 women) had been randomly assigned to receive dexfenfluramine (366 patients), investigational sustaine

8 different in treated and untreated subjects (dexfenfluramine, 9.0%; phentermine/fenfluramine, 4.0%; a

9 Fluoxetine, sibutramine, sertraline and dexfenfluramine all produced a significant reduction in

10 dence interval, 2.9 to 56.4) with the use of dexfenfluramine alone, 24.5 (5.9 to 102.2) with the use

11 We examined patients who had taken dexfenfluramine alone, dexfenfluramine and phentermine,

12 ients who took fenfluramine and phentermine, dexfenfluramine alone, or dexfenfluramine and phentermin

13 disorders in persons taking fenfluramine or dexfenfluramine alone, particularly for more than three

14 athic valvular disorders, 5 after the use of dexfenfluramine and 6 after the use of fenfluramine.

15 specific serotonin releaser-uptake inhibitor dexfenfluramine and alterations in the expression of sev

16 agents and updates the evidence associating dexfenfluramine and fenfluramine with valvulopathy.

17 ntitate brain levels of the fluorinated drug dexfenfluramine and its active metabolite dex-norfenflur

18 In contrast, dexfenfluramine and MDMA depleted brain serotonin and pr

19 Dexfenfluramine and MDMA, on the other hand, markedly de

20 e and phentermine, dexfenfluramine alone, or dexfenfluramine and phentermine had a significantly high

21 e alone, 24.5 (5.9 to 102.2) with the use of dexfenfluramine and phentermine, and 26.3 (7.9 to 87.1)

22 atients who had taken dexfenfluramine alone, dexfenfluramine and phentermine, or fenfluramine and phe

23 Our data indicate that use of dexfenfluramine and phentermine/fenfluramine is associat

24 s, 1473 were eligible (479 and 455 had taken dexfenfluramine and phentermine/fenfluramine, respective

25 and 13 to 26 months after discontinuation of dexfenfluramine and phentermine/fenfluramine.

26 trial comparing dexfenfluramine with regular dexfenfluramine and placebo.

27 en the dietary suppressants fenfluramine and dexfenfluramine and valvular heart disease was first des

28 Appetite suppressants fenfluramine, dexfenfluramine, and phentermine have been used alone or

29 Anorexigens such as aminorex fumarate and dexfenfluramine are associated with the development of s

30 Using dexfenfluramine as unconditional stimulus (US), the auth

31 veloped flavor avoidance with either LiCl or dexfenfluramine as US.

32 Patients received 15 mg dexfenfluramine BID for 90 days.

33 Valve regurgitation has been associated with dexfenfluramine, but its prevalence and severity are unc

34 Dexfenfluramine causes reversible membrane depolarizatio

35 itral regurgitation in patients treated with dexfenfluramine compared with placebo.

36 Measured brain dexfenfluramine/nor-dexfenfluramine concentrations were well below levels pr

37 n, with an investigational sustained-release dexfenfluramine (Dexfen SR), or with a placebo, with ech

38 hree to five months after discontinuation of dexfenfluramine (Dexfen) therapy.

39 he brain concentration of the anorectic drug dexfenfluramine (DF) in human subjects receiving clinica

40 The acute appetite suppressant effect of dexfenfluramine (DF) in rats, which may depend upon its

41 The first agent is the serotonergic agonist, dexfenfluramine (DFEN) and the second is the pancreatic

42 of fluoxetine, sibutramine, sertraline, and dexfenfluramine for 4 days on brain serotonergic nerve t

43 among those who took either fenfluramine or dexfenfluramine for less than four months (95 percent co

44 s phentermine (fen-phen) and the approval of dexfenfluramine gave rise to widespread, long-term use o

45 exigen-treated patients and were 8.9% in the dexfenfluramine group (RR, 2.18; 95% confidence interval

46 .8 percent of those in the sustained-release dexfenfluramine group, 5.4 percent of those in the two a

47 curred in 5.0 percent of the patients in the dexfenfluramine group, 5.8 percent of those in the susta

48 0 (3.3) months (range, 1-18.4 months) in the dexfenfluramine group, and 11.9 (10.4) months (range, 1.

49 ased aortic regurgitation (P = 0.003 for the dexfenfluramine group, P = 0.02 for the sustained-releas

50 up, a greater proportion of patients in both dexfenfluramine groups had decreased aortic regurgitatio

51 gurgitation were considered and when the two dexfenfluramine groups were combined, there was a higher

52 p to 30% to 38% of users of fenfluramine and dexfenfluramine had valvular disease, these drugs were w

53 One of these, dexfenfluramine, has been withdrawn because of fenfluram

54 Fenfluramine and dexfenfluramine have been demonstrated to damage brain s

55 n important clinical problem, and the use of dexfenfluramine hydrochloride for weight reduction has b

56 rfused rat lung, aminorex, fenfluramine, and dexfenfluramine induce a dose-related increase in perfus

57 e, we found that aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in smooth musc

58 ginine methyl ester, the pressor response to dexfenfluramine is greatly enhanced.

59 reatment with phentermine, fenfluramine, and dexfenfluramine is now becoming clarified with the publi

60 came to be associated with fenfluramine and dexfenfluramine, leading to their eventual withdrawal fr

61 aised that the d-enantiomer of fenfluramine, dexfenfluramine, may also cause this problem.

62 Measured brain dexfenfluramine/nor-dexfenfluramine concentrations were

63 The use of fenfluramine or dexfenfluramine, particularly for four months or longer,

64 had decreases; 1 [0.2%] had an increase); 29 dexfenfluramine patients (23 [6.4%] had decreases; 6 [1.

65 o more frequent mild aortic regurgitation in dexfenfluramine patients (6.3% versus 1.6% in controls;

66 gitation) was significantly more frequent in dexfenfluramine patients (7.6% versus 2.1% for controls;

67 subjects meeting the same entry criteria (51 dexfenfluramine patients and 17 controls).

68 he total sample of 412 subjects included 172 dexfenfluramine patients and 172 unexposed controls matc

69 of drug to follow-up echocardiogram for 371 dexfenfluramine patients was 17.5 months (range, 13-26 m

70 Dexfenfluramine-related valve regurgitation may regress

71 , the appetite suppressants fenfluramine and dexfenfluramine, the dopamine agonists pergolide and cab

72 or progress 1 year after discontinuation of dexfenfluramine therapy has not been determined.

73 After dexfenfluramine therapy is taken for 2 to 3 months and d

74 d, double-blind, placebo-controlled study of dexfenfluramine to include echocardiographic examination

75 Dexfenfluramine use is associated with an increase in th

76 Dexfenfluramine was approved in the United States for lo

77 itral regurgitation in patients treated with dexfenfluramine was small, and the degree of regurgitati

78 Fenfluramine and dexfenfluramine were voluntarily withdrawn from the mark

79 late serotonin release and reuptake, such as dexfenfluramine, were withdrawn from sale because of CLH

80 tion by modifying an ongoing trial comparing dexfenfluramine with regular dexfenfluramine and placebo